期刊文献+

Lowry法测定人凝血因子Ⅷ蛋白含量 被引量:7

Determination of protein assay of human coagulation factor Ⅷ by Lowry method
下载PDF
导出
摘要 目的:对Lowry法应用于人凝血因子Ⅷ蛋白含量测定中的可行性进行研究。方法:考察S公司人凝血因子Ⅷ原液及成品,比较凯氏定氮法与Lowry法对蛋白测定结果产生的差异,及不同浓度保护剂对Lowry法的影响。结果:甘露醇对蛋白含量测定有明显正干扰,甘氨酸有负干扰;对样品进行预稀释,辅料在低浓度范围内,当甘露醇浓度为0.1%和甘氨酸浓度为0.3%时,可减少辅料的干扰作用。结论:适当稀释样品可减少保护剂的干扰,用Lowry法测定人凝血因子Ⅷ蛋白含量,简单快速准确可行。 Objective :To determine the protein content in human coagulation factor Ⅷ(FⅧ)by Lowry method. Methods:Lowry method can he used to investigate 3 samples from S company compared with kjeldahl method at the present of different interfering substances. Results:The data showed that mannitol for determination of protein content had significant positive interference, however, glycine had a contrary tendency. The present of 0.1% mannitol and 0.3% glycine showed less interference to the determination result by Lowry method at concentrations of pre-dilute samples. Conclusions: Lowry method can be used to determine protein content of human coagulation factor Ⅷ at certain low concentration solution, which is simple, rapid and feasible.
出处 《北方药学》 2014年第12期27-29,共3页 Journal of North Pharmacy
关键词 人凝血因子Ⅷ 蛋白含量 Lowry法 Human coagulation factorⅧ Protein determination Lowry method
  • 相关文献

参考文献9

二级参考文献70

  • 1郑丽钦.探讨甘氨酸、甘露醇对Lowry法测蛋白含量的干扰[J].海峡药学,2006,18(3):81-83. 被引量:6
  • 2张一折,滕洪刚,吕帅然,姜春来,于湘晖,孔维.重组HIV-1腺病毒载体活疫苗的冻干保护剂研究[J].中国生物制品学杂志,2007,20(2):104-106. 被引量:10
  • 3杨钊 王凤山.小牛胸腺来源低分子免疫抑制组分的分离、纯化性质研究[D].济南:山东大学,2001.
  • 4Liao YH, Brown MB, Quader A,et aL Protective mechanism of stabilizing excipients against dehydration in the freeze-drylng of proreins, Pharm Res ,2002,19 (12) : 1854-1861.
  • 5Souillac PO, Middaugh CR, Rytting JH. Investigation of protein/ carbohydrate interactions in the dried state. 2. Diffuse reflectance FTIR studies. Int J Pharm ,2002,235 (1-2) :207-218.
  • 6Pikal-Cleland If, A, Cleland JL, Anchordoquy TJ, et aL Effect of glycine on pH changes and protein stability during freeze-thawing in phosphate buffer systems. J Pharm Sci, 2002,91 ( 9 ) : 1969- 1979.
  • 7Schwarzinger L, Pabinger I, Kominger C, et al. Incidence of inhibitors in patients with severe and moderate hemophilia a treated with factor Ⅷ concentrates. Am J Hematol,2006,24 (3) :241- 245.
  • 8Arrighi S,Rossi R,Borri M G,et al. In vitro and in animal model studies on a double virus-inactivated factor Ⅷ concentrate. Thromb Haemost, 1995,74 (3) : 868-873.
  • 9Dichtelmtlller H, Rudnick D, Breuer B, et al. Improvement of virus safety of a S/D-treated factor Ⅷ concentrate by additional dry heat treatment at 100℃. Biologicals, 1996,24 (2) : 125-130.
  • 10Brodniewicz-Proba T, Beauregard D. Modified glycine precipitation technique for the preparation of factor Ⅷ concentrate high purity and high stability. Vox Sang, 1987,52 (1-2) : 10-14.

共引文献84

同被引文献60

引证文献7

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部